Watch: New Cancer Drugs from Artificial Life

In 2014 artificial life was made for the first time.

Two new nucleotides were added—X and Y—to the standard four: A, G, T, C

These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.

Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.

Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.

By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.

So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.

http://www.sandiegouniontribune.com/business/biotech/sd-me-synthorx-cancer-20180430-story.html

Follow us on social media for the latest updates in B2B!

Image

Latest

comedy
Laughter as a Service: How Comedy Can Power Trust, Teamwork, and Career Growth
February 19, 2026

Comedy might be the most underused business skill in your toolkit… In a world of back-to-back Zoom calls, Slack threads, and AI-generated everything, real human connection can start to feel like an afterthought. We’re moving faster than ever, but sometimes we’re listening less, reacting more, and missing the small moments that actually build trust. The…

Read More
founder-led brand
The Art of Evolution: Leading a Founder-Led Brand Into Its Next Chapter with Mary Beth Sheridan
February 19, 2026

For many retail brands, growth today isn’t just about innovation — it’s about keeping pace with customers whose expectations are evolving in real time, led by younger generations who expect brands to reflect their values and show up with cultural relevance. In fact, recent research from MG2 found that the overwhelming majority of Gen Z…

Read More
computer vision
Censis’ Final Check Uses Computer Vision to Eliminate Tray Errors Before They Reach the OR
February 19, 2026

Artificial intelligence used to live in strategy decks and conference keynotes—but now it’s showing up in a very different place: right on the assembly tables where SPD technicians build trays for the next case. And it’s arriving at a time when the pressure on sterile processing has never been higher. As surgical volumes climb and…

Read More
Scaling AI
QumulusAI Provides A Clear Roadmap for Scaling AI Platforms to Thousands of Users
February 18, 2026

Scaling AI platforms can raise questions about how to expand across locations and support higher user volumes. Growth often requires deployments in multiple data centers and regions. Mazda Marvasti, the CEO of Amberd, says having a clear path to scale is what excites him most about the company’s current direction. He notes that expanding…

Read More